Smoking Cessation Intervention Within the Framework of a Lung Cancer Screening Program: Preliminary Results and Clinical Perspectives from the “Cosmos-II” Trial

Lococo, Filippo; Principe, Rosastella; Cesario, Alfredo; Apolone, Giovanni; Carleo, Francesco; Ialongo, Pasquale; Veronesi, Giulia; Cardillo, Giuseppe

doi:10.1007/s00408-014-9661-y

Cited by 23 publications

(18 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there is some evidence that a positive screening test result increases the smoking cessation rate 11. Our own data from the Cosmos-II trial (CT lung cancer screening in Italian population) support this 9. Similar to UKLS, we found that ‘high-risk’ subjects, according to a personalised risk model, requiring an additional CT scan were more likely to quit smoking compared with ‘low-risk’ subjects.…”

supporting

confidence: 71%

Does a lung cancer screening programme promote smoking cessation?

Lococo

Cardillo

Veronesi

2017

Thorax

Self Cite

View full text Add to dashboard Cite

supporting

confidence: 71%

Does a lung cancer screening programme promote smoking cessation?

Lococo

Cardillo

Veronesi

2017

Thorax

Self Cite

View full text Add to dashboard Cite

“…More studies on both the positive and negative aspects are required to enrich the conclusion and make further efforts to reduce morbidity and mortality from lung cancer. 26,IC 95%=0,78,P=0,193). Anualmente, o rastreamento de LDCT foi sensível em encontrar mais cânceres de pulmão.…”

Section: Resultsunclassified

Low-dose CT screening can reduce cancer mortality: A meta-analysis

Tang

Wang

et al. 2019

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SUMMARY OBJECTIVE Lung cancer is the leading cause of cancer-related death. To reduce lung cancer mortality and detect lung cancer in early stages, low dose CT screening is required. A meta-analysis was conducted to verify whether screening could reduce lung cancer mortality and to determine the optimal screening program. METHODS We searched PubMed, Web of Science, Cochrane library, ScienceDirect, and relevant Chinese databases. Randomized controlled trial studies with participants that were smokers older than 49 years (smoking >15 years or quit smoking 10 or 15 years ago) were included. RESULTS Nine RCT studies met the criteria. LDCT screening could find more lung cancer cases (RR=1.58, 95%CI=1.25-1.99, P<0.001) and more stage I lung cancers (RR=3.45, 95%CI=2.08-5.72, P<0.001) compared to chest-X ray or the no screening group. This indicated a statistically significant reduction in lung-cancer-specific mortality (RR=0.84, 95%CI=0.75-0.95, P=0.004), but without a statistically reduction in mortality due to all causes (RR=1.26, 95%CI=0.89-1.78, P=0.193). Annually, LDCT screening was sensitive in finding more lung cancers. CONCLUSIONS Low-dose CT screening is effective in finding more lung cancer cases and decreasing the deaths from lung cancer. Annual low-dose CT screening may be better than a biennial screening to detect more early-stage lung cancer cases.

show abstract

“…68 Plasma samples that were prospectively collected during the COSMOS II screening trial have been profiled to set up and validate the clinical utility of the microRNAsignature based miR-Test. 69 The DECAMP-1 and DECAMP-2 prospective observational trials (NCT01785342 and NCT02504697) have been designed to examine a variety of existing biomarkers for lung cancer diagnosis as well as new biomarkers discovered specifically in this clinical setting. DECAMP-1 seeks to improve follow-up of patients with IPNs by determining whether analyzed biomarkers are able to distinguish incidentally detected malignant from benign pulmonary nodules in high-risk smokers, whereas DECAMP-2 will test biomarkers of risk in screened asymptomatic high-risk individuals.…”

Section: Current Trials In Which Biomarkers Are Considered or Includedmentioning

confidence: 99%

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

Seijó

Peled

Ajona

et al. 2019

Journal of Thoracic Oncology

355

275

View full text Add to dashboard Cite

The present review is an update of the research and development efforts regarding the use of molecular biomarkers in the lung cancer screening setting. The two main unmet clinical needs, namely, the refinement of risk to improve the selection of individuals undergoing screening and the characterization of undetermined nodules found during the computed tomography-based screening process are the object of the biomarkers described in the present review. We first propose some principles to optimize lung cancer biomarker discovery projects. Then, we summarize the discovery and developmental status of currently promising molecular candidates, such as autoantibodies, complement fragments, microRNAs, circulating tumor DNA, DNA methylation, blood protein profiling, or RNA airway or nasal signatures. We also mention other emerging biomarkers or new technologies to follow, such as exhaled breath biomarkers, metabolomics, sputum cell imaging, genetic predisposition studies, and the integration of nextgeneration sequencing into study of circulating DNA. We also underline the importance of integrating different

show abstract

Smoking Cessation Intervention Within the Framework of a Lung Cancer Screening Program: Preliminary Results and Clinical Perspectives from the “Cosmos-II” Trial

Cited by 23 publications

References 8 publications

Does a lung cancer screening programme promote smoking cessation?

Does a lung cancer screening programme promote smoking cessation?

Low-dose CT screening can reduce cancer mortality: A meta-analysis

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

Contact Info

Product

Resources

About